A mouse model for Candida glabrata hematogenous disseminated infection starting from the gut: evaluation of strains with different adhesion properties.
PLoS One. 2013;8(7):e69664
Authors: Atanasova R, Angou…
Intra-abdominal fungal infections.
Curr Opin Infect Dis. 2013 Oct;26(5):441-6
Authors: Rebolledo M, Sarria JC
PURPOSE OF REVIEW: The clinical spectrum of intra-abdominal fungal infec…
Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications.
Clin Pharmacokinet. 2014 Mar 5;
Authors: Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, Stiers J, Spigarelli MG, Sherwin CM
Invasive fungal infections are a significant cause of morbidity and mortality in children. Successful management of these systemic infections requires identification of the causative pathogen, appropriate antifungal selection, and optimisation of its pharmacokinetic and pharmacodynamic properties to maximise its antifungal activity and minimise toxicity and the emergence of resistance. This review highlights salient scientific advancements in paediatric antifungal pharmacotherapies and focuses on pharmacokinetic and pharmacodynamic studies that underpin current clinical decision making. Four classes of drugs are widely used in the treatment of invasive fungal infections in children, including the polyenes, triazoles, pyrimidine analogues and echinocandins. Several lipidic formulations of the polyene amphotericin B have substantially reduced the toxicity associated with the traditional amphotericin B formulation. Monotherapy with the pyrimidine analogue flucytosine rapidly promotes the emergence of resistance and cannot be recommended. However, when used in combination with other antifungal agents, therapeutic drug monitoring of flucytosine has been shown to reduce high peak flucytosine concentrations, which are strongly associated with toxicity. The triazoles feature large inter-individual pharmacokinetic variability, although this pattern is less pronounced with fluconazole. In clinical trials, posaconazole was associated with fewer adverse effects than other members of the triazole family, though both posaconazole and itraconazole display erratic absorption that is influenced by gastric pH and the gastric emptying rate. Limited data suggest that the clinical response to therapy may be improved with higher plasma posaconazole and itraconazole concentrations. For voriconazole, pharmacokinetic studies among children have revealed that children require twice the recommended adult dose to achieve comparable blood concentrations. Voriconazole clearance is also affected by the cytochrome P450 (CYP) 2C19 genotype and hepatic impairment. Therapeutic drug monitoring is recommended as voriconazole pharmacokinetics are highly variable and small dose increases can result in marked changes in plasma concentrations. For the echinocandins, the primary source of pharmacokinetic variability stems from an age-dependent decrease in clearance with increasing age. Consequently, young children require larger doses per kilogram of body weight than older children and adults. Routine therapeutic drug monitoring for the echinocandins is not recommended. The effectiveness of many systemic antifungal agents has been correlated with pharmacodynamic targets in in vitro and in murine models of invasive candidiasis and aspergillosis. Further study is needed to translate these findings into optimal dosing regimens for children and to understand how these agents interact when multiple antifungal agents are used in combination.
PMID: 24595533 [PubMed – as supplied by publisher]
Micafungin: an evidence-based review of its place in therapy.
Core Evid. 2014;9:27-39
Authors: de la Torre P, Reboli AC
Invasive fungal infections have increased throughout the world….
Development and antimicrobial susceptibility studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus fumigatus and Pseudomonas aeruginosa.
BMC Microbiol. 2014 Mar 3;14(1):53
Effectiveness of Primary anti-Aspergillus Prophylaxis During Remission Induction Chemotherapy of Acute Myeloid Leukemia.
Antimicrob Agents Chemother. 2014 Mar 3;
Authors: Gomes MZ, Jiang Y, Mulanovich VE, Lew…
Fluconazole administration leading to anaphylactic shock in a preterm newborn.
Neonatal Netw. 2014 Mar-Apr;33(2):83-5
Authors: Koklu E, Kalay S, Koklu S, Ariguloglu EA
Invasive aspergillosis in patients with cirrhosis, a case report and review of the last 10 years.
Acta Clin Belg. 2013 Sep-Oct;68(5):368-75
Authors: Jeurissen S, Vogelaers D, Sermijn E, Van Dycke K, Geerts A,…
Current ciprofloxacin usage in children hospitalized in a referral hospital in Paris.
BMC Infect Dis. 2013;13:245
Authors: Yang ZT, Zahar JR, Méchaï F, Postaire M, Blanot S, Balfagon-Viel S, Nassif X, Lortholary O
BACKGROUND: Fluoroquinolones are used with increasing frequency in children with a major risk of increasing the emergence of FQ resistance. FQ use has expanded off-label for primary antibacterial prophylaxis or treatment of infections in immune-compromised children and life-threatening multi-resistant bacteria infections. Here we assessed the prescriptions of ciprofloxacin in a pediatric cohort and their appropriateness.
METHODS: A monocenter audit of ciprofloxacin prescription was conducted for six months in a University hospital in Paris. Infected site, bacteriological findings and indication, were evaluated in children receiving ciprofloxacin in hospital independently by 3 infectious diseases consultants and 1 hospital pharmacist.
RESULTS: Ninety-eight ciprofloxacin prescriptions in children, among which 52 (53.1%) were oral and 46 (46.9%) parenteral, were collected. 45 children had an underlying condition, cystic fibrosis (CF) (21) or an innate or acquired immune deficiency (24). Among CF patients, the most frequent indication was a broncho-pulmonary Pseudomonas aeruginosa infection (20). In non-CF patient, the major indications were broncho-pulmonary (25), urinary (8), intra-abdominal (7), operative site infection (5) and bloodstream/catheter (2/4) infection. 62.2% were microbiologically documented. Twenty-three (23.4%) were considered «mandatory», 48 (49.0%) «alternative» and 27 (27.6%) «unjustified».
CONCLUSION: In our university hospital, only 23.4% of fluoroquinolones prescriptions were mandatory in children, especially in Pseudomonas aeruginosa healthcare associated infection. Looking to the ecological risk of fluoroquinolones and the increase consumption in children population we think that a control program should be developed to control FQ use in children. It could be done with the help of an antimicrobial stewardship team.
PMID: 23710669 [PubMed – indexed for MEDLINE]
Developments in pediatric infectious diseases: a review of WSPID 2013.
Expert Rev Anti Infect Ther. 2014 Mar 3;
Authors: Eley BS, Nuttall J
8th World Congress of the World Society for…